

# Contents

|                                                                                     |           |
|-------------------------------------------------------------------------------------|-----------|
| <b>Contributors</b>                                                                 | <b>ix</b> |
| <b>Preface</b>                                                                      | <b>xi</b> |
| <br>                                                                                |           |
| <b>1. Pathogen and host genetics underpinning cryptococcal disease</b>              | <b>1</b>  |
| Carolina Coelho and Rhys A. Farrer                                                  |           |
| 1. Introduction                                                                     | 2         |
| 2. <i>Cryptococcus</i> spp. genetics and genomics                                   | 3         |
| 3. Cryptococcosis                                                                   | 30        |
| Acknowledgments                                                                     | 46        |
| References                                                                          | 46        |
| <br>                                                                                |           |
| <b>2. Role of RNA-interacting proteins in modulating plant-microbe interactions</b> | <b>67</b> |
| Saurabh Pandey, Namisha Sharma, and Manoj Prasad                                    |           |
| 1. Introduction                                                                     | 68        |
| 2. Crossing barriers: HIGS into action                                              | 76        |
| 3. RNA-interacting proteins at the verge of plant-pathogen interaction              | 77        |
| 4. RNA chaperone-sRNA interplay in host-microbe interaction                         | 78        |
| 5. Pathogenic sRNAs to impede host defense                                          | 85        |
| 6. sRNAs on the move: Mechanistic insights into cross-kingdom sRNA movement         | 86        |
| 7. Concluding remarks                                                               | 87        |
| Acknowledgments                                                                     | 88        |
| References                                                                          | 88        |
| <br>                                                                                |           |
| <b>3. FMRP ribonucleoprotein complexes and RNA homeostasis</b>                      | <b>95</b> |
| Gabriela Aparecida Marcondes Suardi and Luciana Amaral Haddad                       |           |
| 1. Introduction                                                                     | 96        |
| 2. <i>FMR1</i> -associated clinical conditions                                      | 99        |
| 3. FMRP is a synaptic regulator                                                     | 104       |
| 4. FMRP in ribonucleoprotein (RNP) complexes                                        | 106       |
| 5. Concluding remarks                                                               | 120       |
| Acknowledgments                                                                     | 121       |
| References                                                                          | 121       |

|                                                                                                                 |            |
|-----------------------------------------------------------------------------------------------------------------|------------|
| <b>4. "Electrifying dysmorphology": Potassium channelopathies causing dysmorphic syndromes</b>                  | <b>137</b> |
| Mark James Hamilton and Mohnish Suri                                                                            |            |
| 1. Introduction                                                                                                 | 138        |
| 2. Potassium channel structure and function                                                                     | 139        |
| 3. Andersen-Tawil syndrome                                                                                      | 141        |
| 4. Bauer-Tartaglia (FHEIG) syndrome                                                                             | 145        |
| 5. Birk-Barel syndrome (BBS)                                                                                    | 148        |
| 6. Cantú syndrome                                                                                               | 150        |
| 7. Keppen-Lubinsky syndrome (KLS)                                                                               | 154        |
| 8. Temple-Baraitser syndrome (TBS)                                                                              | 158        |
| 9. Zimmermann-Laband syndrome (ZLS)                                                                             | 162        |
| 10. Conclusions                                                                                                 | 166        |
| Acknowledgments                                                                                                 | 167        |
| References                                                                                                      | 167        |
| <b>5. Recent advances in oomycete genomics</b>                                                                  | <b>175</b> |
| Jamie McGowan and David A. Fitzpatrick                                                                          |            |
| 1. The oomycetes                                                                                                | 176        |
| 2. Oomycete genomes                                                                                             | 180        |
| 3. Oomycete phylogenomics                                                                                       | 190        |
| 4. Oomycete mitochondrial genomes                                                                               | 194        |
| 5. The impact of horizontal gene transfer on oomycete evolution                                                 | 196        |
| 6. Genome mining for oomycete effectors                                                                         | 199        |
| 7. Oomycete OMICS studies                                                                                       | 206        |
| 8. Tools for oomycete genomics                                                                                  | 212        |
| 9. Oomycetes in the post-genomic era                                                                            | 214        |
| 10. Conclusions and future outlook                                                                              | 217        |
| Acknowledgments                                                                                                 | 218        |
| References                                                                                                      | 218        |
| <b>6. Antibiotic drug discovery: Challenges and perspectives in the light of emerging antibiotic resistance</b> | <b>229</b> |
| Keshab Bhattarai, Rina Bastola, and Bikash Baral                                                                |            |
| 1. Introduction                                                                                                 | 231        |
| 2. History of novel antibiotic discovery                                                                        | 232        |
| 3. Metabolite biosynthesizing microbes                                                                          | 234        |
| 4. Antibiotics classification and their mode of actions                                                         | 235        |
| 5. Antibiotic resistance and evolution of superbugs                                                             | 235        |

|                                                                                                                                           |            |
|-------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 6. Problem of antimicrobial resistance                                                                                                    | 237        |
| 7. Foundation of antibiotic era                                                                                                           | 238        |
| 8. Qualities to qualify as an antibiotic                                                                                                  | 238        |
| 9. Antibiotics developmental pipeline and causes of discovery void                                                                        | 239        |
| 10. Maintenance of antibiotics pipeline                                                                                                   | 240        |
| 11. Metabolites detection                                                                                                                 | 241        |
| 12. Metabolites profiling                                                                                                                 | 244        |
| 13. Characteristics of versatile surrogate chassis hosts                                                                                  | 245        |
| 14. Silent/cryptic gene clusters, their roles and significance                                                                            | 246        |
| 15. Secondary metabolic cluster (presence of biosynthetic, resistance and transporters)                                                   | 247        |
| 16. Complex cascade regulation of antibiotic biosynthesis in actinomycetes (Nikkomycin biosynthetic cluster as an example)                | 247        |
| 17. Classical approaches for detection of novel antibiotics                                                                               | 250        |
| 18. Bioactivity analysis of novel antimicrobial compounds                                                                                 | 258        |
| 19. Strategies for prediction, analysis and activation of BGC                                                                             | 259        |
| 20. Alternative approaches to conventional antibiotics                                                                                    | 270        |
| 21. Perspectives, challenges and conclusions                                                                                              | 274        |
| References                                                                                                                                | 275        |
| <b>7. Application of yeast to studying amyloid and prion diseases</b>                                                                     | <b>293</b> |
| Yury O. Chernoff, Anastasia V. Grizel, Aleksandr A. Rubel,<br>Andrew A. Zelinsky, Pavithra Chandramowliswaran,<br>and Tatiana A. Chernova |            |
| 1. Introduction                                                                                                                           | 296        |
| 2. Overview of yeast prions                                                                                                               | 300        |
| 3. Yeast models for polyglutamine aggregation                                                                                             | 308        |
| 4. Yeast models for aggregation of $\alpha$ -synuclein, associated with Parkinson's disease (PD)                                          | 317        |
| 5. Yeast models for amyloid proteins associated with Alzheimer's disease (AD) and tauopathies                                             | 320        |
| 6. Yeast models for aggregation of mammalian prion protein (PrP)                                                                          | 329        |
| 7. Yeast models for proteins associated with amyotrophic lateral sclerosis (ALS)                                                          | 335        |
| 8. Aggregation of transthyretin in yeast                                                                                                  | 346        |
| 9. Yeast assay for amyloid nucleation by mammalian proteins                                                                               | 347        |
| 10. Conclusions and future directions                                                                                                     | 352        |
| Acknowledgments                                                                                                                           | 354        |
| References                                                                                                                                | 354        |